Biological Dynamics to Participate in the Nephron Research Liquid Biopsy Innovation Symposium
/Wednesday, June 16, 2021 at 12:10 p.m. ET / 9:10 a.m. PT
June 15, 2021 09:30 AM Pacific Daylight Time
SAN DIEGO--(BUSINESS WIRE)--Biological Dynamics, Inc., a next-generation liquid biopsy company focused on detecting cancers at the earliest stages, will participate in the Nephron Research Liquid Biopsy Innovation Symposium.
CEO Raj Krishnan, Ph.D. and CFO Kevin Han, will be joined by Dr. Dave Hoon, Professor and Director, Translational Molecular Medicine and Genome Sequencing at Saint John's Cancer Institute to collaborate in a panel discussion, Novel Approaches for Early Cancer Detection, on Wednesday, June 16, 2021, at 12:10 p.m. ET / 9:10 a.m. PT.
Biological Dynamics will discuss a transformative approach to cancer screening using a proprietary platform that enables the isolation and evaluation of non-DNA biomarkers, such as exosomes, exo-proteins, and surfaceomes. The company will also discuss how the access to these differentiated biomarkers from blood can empower cancer detection at the earliest stages.
About Biological Dynamics
Biological Dynamics, Inc. is a healthcare company committed to improving global health outcomes by detecting diseases at their earliest stages. The company's proprietary platform simplifies access to native-state biomarkers and nanoparticles, enabling differentiated multiomics applications. The company is applying its platform technology along with machine learning to detect cancers in blood. For more information, please visit www.biologicaldynamics.com and follow us at @BiodynSD on Twitter.
Contacts
Investor Contact:
Kevin Han
Chief Financial Officer
kevin.han@biodyn.io
